

# THE LANCET

## Neurology


### Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Vivekanandam V, Skorupinska I, Jayaseelan DL, et al. Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial. *Lancet Neurol* 2024; **23**: 1004–12.

	Screening (Pre-treatment assessment)		Treatment Phase							
Phone call No:		Randomisation Visit or Call	1	2			3	4		
Visit No:	Screening Visit				1				2	
			Day 2	Week 6	Week 8	Week 9	Day 2 post cross-over	Week 6 post cross-over	Week 8 post cross-over	
Window of flexibility for timing of visits:	+/- 1 week		+/- 5 days	+/- 5 days	+/- 5 days	Washout	+/- 5 days	+/- 5 days	+/- 5 days	
Informed Consent	X									
Medical History	X									
Physical Examination	X								X	
Vital Signs	X									
Eligibility confirmation		X								
Bloods tests (section 8.5)	X								X	
Urinary Pregnancy Test	X			X	X			X		
MBS, TUG, TST, Questionnaires, Participant diary review.		X	X	X	X			X	X	X
Randomisation		X								
IMP administration instructions		X	X	X	X			X	X	X
Adverse Events review			X	X	X			X	X	X
Concomitant Medication review	X	X	X	X	X		X	X	X	
Compliance		X	X	X	X		X	X	X	

Supplementary Appendix 1: Schedule of events



Supplementary Appendix 2: Percentage improvements from baseline after mexiletine and lamotrigine treatment. IVR = interactive voice response diary stiffness score; MBS = Myotonia Behaviour Score; TST = timed stands test; Avg Pain = average pain score on the Brief Pain Inventory; FSS = Fatigue Severity Scale.

Supplementary Appendix 3: Results from Blindedness Questionnaire

Guessed Sequence	Actual Sequence	
	Mexiletine/Lamotrigine (n = 24)	Lamotrigine/Mexiletine (n = 22)
Mexiletine/Lamotrigine	8 (33%)	6 (27%)
Lamotrigine/Mexiletine	8 (33%)	9 (41%)
Unknown	8 (33%)	7 (32%)